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Cotransins are cyclic heptadepsipeptides that bind
the Sec61 translocon to inhibit cotranslational trans-
location of a subset of secreted and type I transmem-
brane proteins. The few known cotransin-sensitive
substrates are all targeted to the translocon by a
cleavable signal sequence, previously shown to be
a critical determinant of cotransin sensitivity. By pro-
filing two cotransin variants against a panel of
secreted and transmembrane proteins, we demon-
strate that cotransin side-chain differences pro-
foundly affect substrate selectivity. Among the
most sensitive substrates we identified is the proin-
flammatory cytokine tumor necrosis factor alpha
(TNF-a). Like all type II transmembrane proteins,
TNF-a is targeted to the translocon by its mem-
brane-spanning domain, indicating that a cleavable
signal sequence is not strictly required for cotransin
sensitivity. Our results thus reveal an unanticipated
breadth of translocon substrates whose expression
is inhibited by Sec61 modulators.
INTRODUCTION
Cotranslational translocation into the endoplasmic reticulum
(ER) is an essential, early step in the biogenesis of secreted
and transmembrane proteins. Selective delivery of these pro-
teins to the ER is initiated when the first hydrophobic domain,
either a cleavable N-terminal signal sequence or an internal
transmembrane domain, emerges from the ribosome. This
hydrophobic domain is initially captured by the signal recognition
particle (SRP), which targets the ribosome-nascent chain com-
plex to the ER membrane via the SRP receptor (Egea et al.,
2005; Halic and Beckmann, 2005). The nascent chain is then1082 Chemistry & Biology 18, 1082–1088, September 23, 2011 ª201transferred to the Sec61 translocon, a multisubunit trans-
membrane protein complex that mediates cotranslational trans-
location and membrane integration of nearly all secreted and
transmembrane proteins (Rapoport, 2007; Mandon, et al.,
2009). Once at the translocon, the signal sequence or transmem-
brane domain is thought to trigger a conformational change in
Sec61a, which opens the translocation channel for polypeptide
entry into the ER lumen and/or the lipid bilayer (Hegde and
Kang, 2008; Plath et al., 1998).
We (Garrison et al., 2005) and another group (Besemer et al.,
2005) previously characterized the biological mechanism of
‘‘cotransins,’’ a class of cyclic heptadepsipeptides structurally
related to the fungal natural product HUN-7293 (compound 1,
Figure 1A). Cotransins potently inhibit the cotranslational trans-
location of a subset of secreted and transmembrane proteins,
resulting in their proteasomal degradation in the cytosol. Mech-
anistic studies with VCAM (vascular cell adhesion molecule-1)
suggested that cotransins inhibit gating of the Sec61 translocon
by the VCAM signal sequence, thereby preventing the nascent
polypeptide from accessing the ER lumen (Figure 1B). Consis-
tent with this model, a clickable photoaffinity probe related to
compound 2 (CT08, Figure 1A) identified the core translocon
subunit, Sec61a, as a direct high-affinity target (MacKinnon
et al., 2007). Moreover, signal sequence swapping experiments
revealed that cotransin sensitivity is determined by the precise
identity of the N-terminal signal sequence (Garrison et al.,
2005; Besemer et al., 2005). Thus, cotransins appear to selec-
tively disrupt the decisive interaction between Sec61a and
a subset of cleavable N-terminal signal sequences.
Given that many proteins with cleavable signal sequences
are attractive therapeutic targets, understanding the basis of
cotransin selectivity is of considerable interest. To date, only
five cotransin-sensitive proteins (VCAM, ICAM-1, E-selectin,
P-selectin, and VEGF-A) have been identified, all of which con-
tain cleavable signal sequences lacking any obvious sequence
similarity (Garrison et al., 2005; Harant et al., 2007; Boger
et al., 1999). Mutagenesis studies have suggested a rough corre-
lation between signal sequence hydrophobicity and cotransin1 Elsevier Ltd All rights reserved
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Figure 1. Cotransins, Cyclic Depsipeptide Inhibitors of Cotranslational Translocation
(A) Chemical structures of HUN-7293, CT08, and CT09.
(B) Cotransins inhibit cotranslational translocation of a subset of secreted and transmembrane proteins by preventing signal sequence-dependent opening of the
Sec61 translocon. Signal recognition particle (SRP); signal recognition particle receptor (SR).
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amore complex relationship (Harant et al., 2006, 2007). Similarly,
little is known about the relationship between cotransin struc-
tural elements (e.g., its amino and hydroxy acid side chains)
and substrate selectivity/promiscuity. An extensive analysis of
HUN-7293 variants revealed that side-chain or backbone modi-
fications can dramatically affect potency (Chen et al., 2002).
However, the analysis of only two secretory protein substrates
in this study (VCAM and intercellular adhesion molecule-1,
ICAM-1) left the issue of selectivity largely unresolved. We there-
fore sought to define a broader range of cotransin-sensitive
secretory and transmembrane substrates, and at the same
time, determine whether substrate selectivity can be altered by
side-chain modifications.
RESULTS AND DISCUSSION
In the structure-activity study described above (Chen et al.,
2002), most of the HUN-7293 variants were at least 20 times
more potent at blocking the expression of VCAM, as compared
with ICAM.Wewere intrigued by the sole exception, a compound
we have named CT09 (compound 3, Figure 1A), which had the
opposite preference, displaying slightly increased potency
against ICAM relative to VCAM. CT09 differs structurally from
HUN-7293 by the presence of an N-benzyl indole, which
replaces theN-methoxy indole at position 5 (Figure 1A). Although
only two secretory proteins were examined, the results of ChenChemistry & Biology 18, 1082–108et al. led us to hypothesize that subtle side-chain differences
could significantly impact cotransins’ selectivity/promiscuity.
We therefore synthesized CT09 and quantified its effects on
the expression of 25 secreted and transmembrane proteins
implicated in autoimmune disease, inflammation, and cancer
(see Table S1 available online). In parallel, we profiled the related
cyclic heptadepsipeptide CT08 (compound 2, Figure 1A), which
we previously found to inhibit VCAM expression at low nanomo-
lar concentrations (MacKinnon et al., 2007). We quantified
endogenously expressed proteins in primary human cells (endo-
thelial, peripheral blood mononuclear, and bronchial epithelial
cells) under stimulatory conditions designed to model human
pathophysiology (Plavec et al., 2004; Berg et al., 2010). Protein
expression levels were quantified by validated immunoassays
(for details, see Supplemental Experimental Procedures).
Strikingly, CT08 and CT09 were equipotent at blocking the
expression of a subset of proteins but had vastly different poten-
cies toward the majority of proteins tested. Based on their rela-
tive sensitivities to CT08 and CT09, the 25 proteins on the panel
can be divided into three classes (for the complete data set, see
Figure S1). The first class comprises only two proteins, VCAM
and TNF-a, both of which were sensitive to low nanomolar
concentrations of CT08 or CT09 (Figure 2A). In the second and
largest class (72% of the panel) are proteins whose expression
was inhibited byCT09muchmore potently thanCT08 (Figure 2B;
Figure S1B). This class is exemplified by the urokinase plasmin-
ogen activator receptor, uPAR (20-fold more sensitive to CT09)8, September 23, 2011 ª2011 Elsevier Ltd All rights reserved 1083
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Figure 2. CT08 and CT09 Differentially Inhibit Secretory and Transmembrane Protein Expression
Primary human cells were stimulated under various proinflammatory conditions (see Supplemental Experimental Procedures for details) in the presence of
increasing concentrations of CT08 or CT09. After 24 hr, expression levels of a total of 25 secreted and membrane proteins (see Table S1 for details) were
quantified by cellular immunoassays and normalized to DMSO controls (mean ± SEM; n = 3). EC50 values were estimated by curve fitting with Prism software (for
the complete set of dose-response curves and 95% confidence intervals, along with EC50 values grouped by system, see Figure S1).
(A) Class I proteins, VCAM and TNF-a, are similarly sensitive to CT08 and CT09.
(B) Class II proteins, uPAR and E-selectin, show greater sensitivity to CT09 than CT08.
(C) Class III proteins, TGF-b1 and MMP-1, show <60% inhibition by 3.3 mM CT09 or CT08.
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Sec61 Modulators Inhibit TNF-a Expressionand the cell adhesion protein, E-selectin (40-fold more sensitive
to CT09). Vascular endothelial growth factor receptor-2
(VEGFR2) provides an extreme example of this selectivity, as it
was unaffected by up to 3.3 mM CT08, yet was maximally in-
hibited by approximately 100 nM CT09 (>80-fold more sensitive
to CT09; Figure S1B). Finally, a third class of proteins (20%of the
panel) was only partially affected by micromolar concentrations
of either CT08 or CT09 (<60% inhibition at 3.3 mM) (Figure 2C;
Figure S1C).
A comparison of CT08 and CT09 EC50 values across the panel
reveals two salient features (Figure 3A). First, CT09 is extremely
potent, inhibiting the expression of most secreted and trans-
membrane proteins at concentrations below 100 nM. By con-
trast, at a concentration of 100 nM, CT08 completely inhibited
the expression of only two proteins VCAMand TNF-a (Figure 2A);
higher concentrations were required to inhibit the expression of1084 Chemistry & Biology 18, 1082–1088, September 23, 2011 ª201most other proteins (Figure 2B; Figure S1B). Second, the data
reveal an unconventional structure-activity relationship: side-
chain differences between CT08 and CT09 (Figure 1B) impart
dramatic potency differences (EC50 ratios) that vary over two
orders of magnitude depending on which secretory protein is
examined (exemplary CT08:CT09 EC50 ratios: approximately
1.7 for VCAM; approximately 20 for uPAR; approximately 200
for CXCL10; Figure 1B). Moreover, the rank order of protein
sensitivity (ranked by increasing EC50) differs between CT08
and CT09. For example, whereas TNF-a is the most CT08-sensi-
tive protein (Figure 3A), there are nine proteins that are equally or
more CT09 sensitive than TNF-a (Figure S1B).
We hypothesized that the differential selectivity with which
CT08 and CT09 inhibit secretory protein expression arises at
the level of cotranslational translocation and that such differ-
ences depend primarily on the signal sequences that mediate1 Elsevier Ltd All rights reserved
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Figure 3. CT08 Is Relatively Selective,
whereas CT09 Is a Highly Promiscuous
Inhibitor
(A) EC50 values for CT08 and CT09 across the
panel of 25 proteins were estimated by curve
fitting with Prism. Proteins are listed in order of
decreasing sensitivity to CT08.
(B) HeLa cells were transfected with plasmids
encoding GFP or GFP containing the signal se-
quence (plus 10 mature domain residues) from
VCAM or Prl fused to the N terminus. Transfected
cells were treated with the indicated concentra-
tions of CT08 or CT09 for 20 hr prior to cell lysis
and western blot analysis with antibodies to GFP.
(C and D) mRNA encoding the indicated proteins
was translated in reticulocyte lysate in the pres-
ence of [35S]-Met, rough ERmicrosomes (RM), and
the indicated concentrations of CT08 or CT09. The
translated material was left untreated or treated
with proteinaseK (PK) and analyzed by SDS-PAGE
followed by autoradiography. Asterisk indicates
translocated VCAM/Prl-GFP.
Chemistry & Biology
Sec61 Modulators Inhibit TNF-a Expressiontranslocon targeting. To test this hypothesis, we generated
constructs containing the signal sequence plus ten mature
domain residues of either VCAM or preprolactin (Prl) fused to
theN terminus of GFP; both constructs also contained aC-termi-
nal ER-retention signal (Snapp et al., 2006). Treatment of
transfected HeLa cells with nanomolar concentrations of either
CT08 or CT09 resulted in an upward shift in the apparent mobility
of VCAM-GFP (Figure 3B), consistent with a lack of signal
sequence cleavage due to inhibition of cotranslational transloca-
tion. By contrast, expression of the mature, signal-cleaved form
of Prl-GFP was relatively insensitive to CT08 (EC50 > 1 mM), yetChemistry & Biology 18, 1082–1088, September 23, 2011 ªwas potently inhibited by CT09 (EC50
approximately 25 nM, Figure 3B). The
apparent reduced stability of full-length
Prl-GFP relative to VCAM-GFP likely
derives from the greater hydrophobicity
of the Prl signal sequence, recently
shown to be an important determinant in
the degradation of secretory proteins
mislocalized to the cytosol (Hessa et al.,
2011). GFP lacking a signal sequence
was unaffected by either CT08 or CT09.
We confirmed the selectivity of CT08
versus CT09 by comparing their effects
in an in vitro translocation system con-
taining reticulocyte lysates and pancre-
atic ER microsomes. Consistent with the
cell-based experiments, in vitro translo-
cation of VCAM-GFP was abolished by
low concentrations of both CT08 and
CT09, whereas Prl-GFP was significantly
more sensitive to CT09 than CT08 (Fig-
ure 3C). These experiments, coupled
with the cell-based experiments in Fig-
ure 3B (VCAM-GFP and GFP constructs),
also demonstrate that neither CT08 nor
CT09 affects translation. Finally, in vitrotranslocation assays confirmed that full-length E-selectin is least
10-fold more sensitive to CT09 (EC50 < 100 nM) than CT08 (Fig-
ure 3D), consistent with the cell profiling experiments. We
conclude that CT09 broadly inhibits cotranslational translocation
and is relatively indiscriminate with respect to signal sequence.
By contrast, sensitivity to CT08 is highly signal sequence
dependent.
We further characterized TNF-a because of its therapeutic
relevance to autoimmune disorders (Palladino et al., 2003) and
its potent inhibition by the more selective cotransin, CT08. It
was particularly important to corroborate TNF-a inhibition in2011 Elsevier Ltd All rights reserved 1085
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Figure 4. CT08 Inhibits Cotranslational
Translocation of TNF-a, a Type II Trans-
membrane Protein that Lacks a Cleavable
Signal Sequence
(A) Expression of TNF-a in COS-7 cells treated
with CT08. Cell lysates were analyzed by western
blotting. NT, not transfected.
(B) mRNA encoding TNF-a was translated in the
presence of [35S]-cysteine and rough ER micro-
somes (RM). The translated material was left
untreated or treated with proteinase K (PK) in the
presence or absence of detergent (det, Triton
X-100). Samples were separated by SDS-PAGE
and analyzed by autoradiography. The positions
of full-length TNF-a (open diamond) and its
protease-protected fragment (solid diamond) are
indicated.
(C) In vitro translation/translocation of TNF-a, as in
Figure 4B. Samples translated in the presence of
increasing concentrations of CT08 were digested
with proteinase K (+PK), separated by SDS-PAGE,
and analyzed by autoradiography and phosphor-
imaging. A dose-response curve was derived by
quantifying the PK-protected TNF-a fragment.
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sin-sensitive translocon substrate that lacks a cleavable signal
sequence. TNF-a is cotranslationally inserted into the ER
membrane with a type II orientation prior to its delivery to the
plasma membrane (Utsumi et al., 1995; Kriegler et al., 1988); it
has a cytoplasmic N-terminal tail, followed by a transmem-
brane-spanning region and an extracellular C-terminal domain
that acts as a proinflammatory cytokine when liberated by extra-
cellular proteases. In lieu of a cleavable signal sequence, the
hydrophobic membrane-spanning domain serves as a ‘‘signal
anchor’’ that mediates SRP-dependent targeting, engagement
of the Sec61 translocon, and insertion into the lipid bilayer. As
such, it is one of four proteins on our panel that relies on an
internal signal anchor for cotranslational translocation (the other
type II transmembrane proteins, HLA-DR, CD38 and CD69, were
affected by higher concentrations of CT08, Figure 3; Figure S1B).
Because the inhibitory effects of CT08 andCT09were revealed
in a complex cellular system (peripheral bloodmononuclear cells
stimulated with LPS) in which endogenous TNF-a expression is
regulated transcriptionally (Collart et al., 1990), posttranscrip-
tionally (Wang et al., 1997; Kontoyiannis et al., 1999), and trans-
lationally (Han et al., 1990), we performed experiments to rule
out indirect effects and test whether CT08 blocks TNF-a at the
level of cotranslational translocation. We focused on CT08,
due to its greater selectivity across the panel and thus lower likeli-
hood of inhibiting TNF-a expression by indirect mechanisms.
We first expressed TNF-a from a cytomegalovirus promoter-
driven plasmid in transiently transfected COS-7 cells. In this
system, CT08 potently inhibited TNF-a expression with an EC50
of less than 60 nM (Figure 4A). As observed with endogenously
expressed proteins in primary human cells, the inhibitory effect1086 Chemistry & Biology 18, 1082–1088, September 23, 2011 ª2011 Elsevier Ltd All rights rof CT08 toward ectopically expressed
TNF-a was similar to its effect on VCAM
expressed under identical conditions
(MacKinnon et al., 2007). To confirm thatCT08 blocks TNF-a expression at the level of cotranslational
translocation, we moved to the in vitro translocation system.
Cotranslational insertion of TNF-a into the microsomal mem-
branes was indicated by the formation of a protease-protected
fragment consisting of its transmembrane and luminal domains.
In the absence of microsomes, or when microsomes were dis-
rupted by detergent, TNF-a was completely digested by added
protease (Figure 4B). Consistent with the results obtained in
transfected cells, cotranslational translocation of wild-type
TNF-a into ER microsomes was inhibited by nanomolar concen-
trations of CT08 (Figure 4C).
The TNF-a validation experiments conclusively demonstrate
that noncleavable signal anchors (found in all type II transmem-
brane proteins and many multispanning membrane proteins)
can be as susceptible as cleavable signal sequences to cotran-
sin-mediated inhibition. This was unexpected because (1)
previous studies indicated that increasing the hydrophobicity
of signal sequences leads to decreased cotransin sensitivity
(Harant et al., 2006, 2007), and (2) signal anchors, by virtue of
their requirement to stably span the lipid bilayer, are universally
more hydrophobic than cleavable signal sequences (Martoglio
and Dobberstein, 1998; Sakaguchi, et al., 1992). Thus, cotransin
sensitivity is not likely based on a single biophysical parameter
such as signal sequence/anchor hydrophobicity, raising the
possibility that more finely tuned cotransin variants with differing
substrate selectivity may be discovered.
SIGNIFICANCE
Prior to this work, cotransin-related cyclodepsipeptides had
been shown to inhibit the expression of only five secretedeserved
Chemistry & Biology
Sec61 Modulators Inhibit TNF-a Expressionand transmembrane proteins, all with cleavable signal
sequences lacking any obvious sequence similarity. We
made the surprising discovery that structural differences
among cotransins (CT08 versus CT09) can drastically alter
the range of inhibited proteins: CT09 inhibited the expres-
sion of 20 out of 25 proteins tested at low nanomolar
concentrations, whereas CT08 exhibited selectivity for
VCAM and TNF-a, affecting most of the remaining proteins
only at higher concentrations. In the future, it may be
possible to refine structure-activity relationships of CT08-
like molecules such that even greater selectivity toward
TNF-a is achieved. Such compounds may provide early
leads for small-molecule anti-inflammatory agents that
block the functional expression of TNF-a.
EXPERIMENTAL PROCEDURES
Chemical Synthesis of Cotransins
CT08 and CT09 were synthesized by adapting published protocols (Chen
et al., 2002; MacKinnon et al., 2007). Intermediates were characterized by
1H and 13C NMR and mass spectrometry. Final compounds were character-
ized by 1H NMR and high-resolution mass spectrometry and found to be in
agreement with published data.
Secretory Protein Profiling
Primary human endothelial, peripheral blood mononuclear, or bronchial
epithelial cells were stimulated under various proinflammatory conditions
(see Supplemental Experimental Procedures for details) in the presence of
increasing concentrations of CT08 or CT09. After 24 hours, protein expression
levels were quantified by cellular immunoassays as previously described (Berg
et al., 2010). Briefly, microtiter plates containing treated and stimulated cells
were blocked and then incubated with primary antibodies for 1 hr. After
washing, plates were incubated with a biotin-conjugated anti-mouse IgG anti-
body for 1 hr, followed by HRP-streptavidin for 30 min. Plates were washed
and developed with TMB substrate. Using a SpectraMAX 190 plate reader
(Molecular Devices), we read the absorbance at 450 nmm. Mean values
were calculated from triplicate samples (±SEM) and expressed as a normalized
ratio versus the DMSO control values. Normalized expression values were
plotted as a function of CT08 and CT09 concentration. EC50 values (with
95% confidence intervals) were estimated by curve fitting with GraphPad
Prism software.
Protein Expression in COS-7 and HeLa Cells
The plasmid encoding human TNF-a was obtained from the PlasmID Reposi-
tory at Harvard Medical School (clone 1319). The coding region was cloned
into pcDNA3.1 (Invitrogen) and used in transient transfection experiments.
COS-7 cells were cultured in high glucose Dulbecco’s modified eagle medium
(DMEM) with 10%FBS at 10%CO2. Cells were seeded in 6-well dishes, grown
to 80% confluency, and transfected with the TNF-a expression plasmid using
Lipofectamine 2000. Five hours after transfection, the media was changed to
include CT08 at the indicated concentrations. After 24 hr, cells were harvested
in lysis buffer (0.5% Triton X-100 in PBS). Lysates were normalized using
the Bradford assay and equal amounts of total protein were resolved by
SDS-PAGE and analyzed by immunoblotting and chemiluminescence. Trans-
fection experiments with GFP (Clontech), Prl-GFPKDEL and VCAM-GFPKDEL
(both in pDNA3.1) were performed similarly except that HeLa cells growing in
24-well dishes were used. Two hours after transfection, cells were treated with
the indicated concentrations of CT08 and CT09 for 20 hr and then lysed in
200 ml 1%SDS, 0.1MTris (pH 8.0). After boiling and shearing theDNA, aliquots
were analyzed by SDS-PAGE and the GFP visualized by western blotting.
In Vitro Cotranslational Translocation Assays
In vitro transcription, translation, translocation, and protease protection
assays were performed as previously described (Sharma et al., 2010). Briefly,
DNA templates were transcribed for 60 min at 37C. Translation reactionsChemistry & Biology 18, 1082–108were performed at 32C for 30 min. Samples were separated by SDS-PAGE,
dried, and exposed to Kodak Biomax MR film. For quantitative analysis of
translocation experiments, dried gels were exposed to a phosphorimaging
screen and quantified using a Typhoon 9400 phosphorimager (Amersham)
with accompanying software.
SUPPLEMENTAL INFORMATION
Supplemental Information includes one figure, one table, and Supplemental
Experimental Procedures and can be found with this article online at doi:10.
1016/j.chembiol.2011.06.015.
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